Pharma Tips

GSK files cancer combination

By: Pharma News | Views: 859 | Date: 29-Jul-2013

GlaxoSmithKline has put in supplemental applications for its Tafinlar/Mekinist combination - a pair of drugs which analysts predict may have peak sales together of £1.5 billion - to the FDA.

GSK files cancer combination

GlaxoSmithKline has put in supplemental applications for its Tafinlar/Mekinist combination - a pair of drugs which analysts predict may have peak sales together of £1.5 billion - to the FDA.

Both Tafinlar (dabrafenib), a BRAF inhibitor, and Mekinist (trametinib), a MEK inhibitor, are currently being looked at by regulators as a treatment for adults with unresectable or metastatic melanoma with a BRAF V600 E or K mutation.

The new applications are based a randomised Phase I/II study comparing Tafinlar on its own to the combination in patients with these mutations.

There is already an ongoing European review of Mekinist as monotherapy and as part of this combination, which was being accelerated - but the CHMP has now slowed to a standard timeframe to allow the submission to be reviewed.

In May the FDA requested more information on Mekinist’s manufacture but GSK will consider it well worth the wait if the two drugs gain approval as a two-in-one treatment.

Melanoma is certainly a prized therapy area, with analysts Decision Resources forecasting a more than seven-fold expansion over the next decade to $1.5 billion in 2020 in the top seven markets of the US, France, Germany, Italy, Spain, the UK and Japan.

Snapping at GSK’s heels is Roche, whose combination of BRAF inhibitor Zelboraf (vemurafenib) - the first drug to increase overall survival in BRAF positive melanoma patients - and MEK inhibitor GADC-0973 is in Phase III testing.

GSK is also developing a diagnostic kit for its drugs in order to assess which patients could best benefit from the new treatments, in collaboration with bioMérieux.

It has filed for FDA pre-market approval of the test which is being studied as part of the Phase III combination programme.

Other companies developing drugs in the class include Array Biopharma/Novartis with MEK 162 and AstraZeneca with selumetinib.

Previous Page Next Page

People Searching On This Page:
  • mekinist
  • pharmaceutical companies in india

Related Pages


Drug industry gears up to fight ban on 329 fixed dose combinations

Drug industry gears up to fight ban on 329 fixed dose combinations

News | FDA
Date:
14-Mar-2016  Views: 2303

harma companies are planning to push hard for the withdrawal of an order by the health ministry last week to ban 329 drugs marketed as "fixed dose com ...
Sun Pharma buys GSK’s Opiates business in Australia

Sun Pharma buys GSK’s Opiates business in Australia

News | Pharma Companies
Date:
03-Mar-2015  Views: 1052

The current GSK Opiates business including related manufacturing sites in Latrobe (Tasmania) and Port Fairy (Victoria) and its portfolio products alon ...
Crocin headache for GSK Healthcare

Crocin headache for GSK Healthcare

News | FDA
Date:
02-Jul-2014  Views: 1592

GlaxoSmithKline Consumer Healthcare has run into trouble with the drug regulator in Maharashtra over the company’s popular fever and pain medicine Cro ...
Gleevec Medicines Fight against Cancer

Gleevec Medicines Fight against Cancer

News | Pharmaceutical Drugs
Date:
14-Oct-2013  Views: 1303

How does Gleevec work? What will it do for me?How should I use Gleevec?What form(s) does Gleevec come in?Who should NOT take Gleevec?What side effects ...
National Cancer Research Institute (NCRI) Cancer Conference 2013

National Cancer Research Institute (NCRI) Cancer Conference 2013

News | Exhibitions & Conferences
Date:
02-Sep-2013  Views: 1446

About NCRIThe NCRI is a UK-wide partnership between government, charity and industry, which promotes co-operation in cancer research. Our 22 member or ...
Post Your Comments (No Login Require)
Name : (required)
Email : (required)
Website :

Comment : (required)

64  + 4 =     
Comments
People Searched About:
Mekinist   |   Pharmaceutical Companies In India   |  
Google : 78 times | Yahoo : 24 times | Bing : 10 times |